Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1002 vs Dapagliflozin in T2DM Inadequately Controlled on Metformin
NCT07082114Phase 3Recruiting
- Sponsor
- Huadong Medicine
- Start
- Jul 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of conveglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Huadong Medicine. Primary endpoint: Change From Baseline in HbA1c at 40 weeks. Started Jul 2025; status: recruiting.
02
Drugs
conveglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07082114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07082114.